Company Encyclopedia
View More
name
ALPS Medical Breakthrough
SBIO.US
News
View More

Chmn Tabuteau Sells 79,973 ($11.6M) Of Axsome Therapeutics Inc [AXSM]

Tabuteau Herriot, Chairman of Axsome Therapeutics Inc, sold 79,973 shares worth $11.6M, as disclosed in a Form 4 filed with the SEC. The transaction was executed under a prearranged trading plan (10b5-1). Ending holdings are 7,351,729 shares. The Washington Service offers insider trading analysis and data services.

Reuters·
US
AXSM
+1.69%
Reuters·
US
AXSM
+1.69%

Axsome Therapeutics CEO Herriot Tabuteau Reports Disposal of Common Shares

Herriot Tabuteau, CEO and Director of Axsome Therapeutics Inc., reported the disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system, with Ref. ID: 0001193125-25-308354, dated December 04, 2025.

Reuters·
US
AXSM
+1.69%
Reuters·
US
AXSM
+1.69%

Attention Long-Term Shareholders of Cytokinetics, Inc.

Grabar Law Office is investigating claims on behalf of long-term shareholders of Cytokinetics, Inc. (NASDAQ: CYTK), Molina Healthcare, Inc. (NYSE: MOH), Synopsys, Inc. (NASDAQ: SNPS), and WEBTOON Entertainment Inc. (NASDAQ: WBTN) due to alleged breaches of fiduciary duties by certain officers and directors. The investigations focus on various issues including misleading statements regarding FDA applications, undisclosed material facts, inflated growth figures, and misleading IPO disclosures. Shareholders who purchased shares before specific dates are encouraged to contact the firm for potential corporate reforms and compensation.

GlobeNewswire·
US
CYTK
-0.82%
US
MOH
+0.12%
GlobeNewswire·
US
CYTK
-0.82%
US
MOH
+0.12%

PTC Therapeutics CEO Makes Significant Stock Sale!

PTC Therapeutics CEO Matthew B. Klein sold 3,428 shares worth $271,051 on December 3, 2025. The company has seen significant stock activity due to strong Q3 earnings and the launch of Sephience. RBC Capital downgraded the stock, while Goldman Sachs and TD Cowen raised their price targets. Despite challenges, the earnings call was positive. TipRanks’ AI Analyst rates PTCT as Outperform, citing strong technical indicators and favorable valuation.

Tip Ranks·
US
PTCT
-0.55%
Tip Ranks·
US
PTCT
-0.55%

CEO Klein Acquires 4,384 Of PTC Therapeutics Inc [PTCT]

CEO Matthew B. Klein of PTC Therapeutics Inc. filed a Form 4 with the SEC, disclosing changes in ownership. On December 1, 2025, he exercised 7,812 shares at $0.00, and on December 2, 2025, he surrendered 3,428 shares at $79.07, valued at $271,052, under a prearranged trading plan (10b5-1). Ending holdings are 349,964 shares directly.

Reuters·
US
PTCT
-0.55%
Reuters·
US
PTCT
-0.55%
© 2025 Longbridge｜Disclaimer